J&J consumer health care division providing 300 reps to detail Alza's pediatric attention hyperactivity deficit disorder Rx drug Concerta following its anticipated late summer launch in the U.S. Approximately 110 McNeil reps will contact pediatricians exclusively, while the rest will detail to general practitioners and family care physicians. Under the agreement with Alza, McNeil will receive payments for its sales efforts and payments based upon specific sales attained. Alza is hoping to leverage McNeil's sales experience in pediatrics with Children's Tylenol and Children's Motrin. The J&J division co-promotes two other Rx drugs: Daiichi's Floxin otic and Allergan's Ocuflox ophthalmic solution
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.
Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
